Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | MLYCD | O95822 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29988585 | 1.00 | MRGPRX4 (0.57) | MRGPRX4HTR2AHTR2BHTR2CCARM1 | |
| Acetic Acid SCHEMBL30416370 | 0.90 | L3MBTL1 (0.58) | MRGPRX4LMNAMAPTMLYCDL3MBTL1 | |
| SCHEMBL13948894 | 0.85 | MRGPRX4 (0.52) | MRGPRX4HTR2ACARM1PRMT6IDO1 | |
| SCHEMBL541044 | 0.84 | TAAR1 (0.58) | HTR2AHTR2BHTR2CTAAR1IDO1 | |
| SCHEMBL4239980 | 0.84 | DPP7 (0.59) | HTR2AHTR2BHTR2CTAAR1IDO1 | |
| SCHEMBL8260091 | 0.82 | PRMT6 (0.49) | MRGPRX4CARM1PRMT6MAPTCYP3A4 | |
| SCHEMBL3920885 | 0.81 | TAAR1 (0.61) | HTR2AHTR2BHTR2CCARM1PRMT6 | |
| SCHEMBL4240337 | 0.81 | IDO1 (0.54) | HTR2AHTR2BHTR2CCARM1PRMT6 | |
| SCHEMBL2855040 | 0.81 | HTR2A (0.58) | HTR2AHTR2BHTR2CCARM1PRMT6 | |
| SCHEMBL3237564 | 0.81 | TAAR1 (0.64) | HTR2AHTR2BHTR2CTAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| CN-105307651-A | Thiazole compound and application thereof | ABBVIE INC | 2016-02-03 | — | — | CN | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-26 | — | — | US | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116139282-A | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-0619297-B1 | Fungicides for the control of take-all desease of plants | MONSANTO CO (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5498630-A | SUBSTITUTED BENZOTHIOPHENECARBOXAMIDES | MONSANTO COMPANY (US) | 1996-03-12 | — | — | US | disclosed |
| EP-0619297-A1 | Fungicides for the control of take-all desease of plants | MONSANTO COMPANY (US) | 1994-10-12 | — | — | EP | disclosed |
| CN-1085221-A | Bactericide for preventing and treating plant take-all disease | MONSANTO CO (US) | 1994-04-13 | — | — | CN | disclosed |
| WO-1993007751-A1 | FUNGICIDES FOR THE CONTROL OF TAKE-ALL DISEASE OF PLANTS | MONSANTO COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0212479-A1 | Use of lactam amides as efficiency improvers in animals | BAYER AG (DE) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | MRGPRX4 625/4885HTR2A 1540/4885HTR2B 809/4885 |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | MRGPRX4 49/4885HTR2A 760/4885HTR2B 656/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | MRGPRX4 3149/4885HTR2A 1652/4885HTR2B 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.